Abstract
Background
Degenerative ocular diseases such as macular retinopathy and retinal disorders significantly affect vision loss and the quality of life. The prevalence of these ophthalmic diseases is increasing due to surges in the elderly population and diabetes mellitus. Ophthalmic drug delivery systems for intraocular drug delivery have been studied and developed for decades. Due to multiple barriers in the eye, including physiological and anatomic obstacles, many challenges remain for enhanced ocular drug delivery. Currently, only a few approaches are available to treat ocular diseases.
Area covered
This review investigated various barriers in the eye and the current ocular formulations such as intravitreal injections and intravitreal implants. In addition, different types of advanced ophthalmic drug delivery systems, including lens implants, microneedle arrays, micropumps, nano-formulations, sonophoresis, and transscleral iontophoresis, were briefly reviewed.
Expert opinion
Novel ophthalmic dosage forms for drug delivery to the posterior segment should be developed to achieve a safe therapeutic effect. If some achievements can be established in further studies, the paradigm of chronic ocular diseases can be shifted to home-based self-administration, thus improving the therapeutic efficacy and the patient’s quality of life.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agrahari V, Mandal A, Agrahari V et al (2016) A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res 6:735–754. https://doi.org/10.1007/s13346-016-0339-2
Al-Halafi AM (2014) Nanocarriers of nanotechnology in retinal diseases. Saudi J Ophthalmol 28:304–309. https://doi.org/10.1016/j.sjopt.2014.02.009
Araújo J, Nikolic S, Egea MA et al (2011) Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surf B 88:150–157. https://doi.org/10.1016/j.colsurfb.2011.06.025
Bachu RD, Chowdhury P, Al-Saedi ZHF et al (2018) Ocular drug delivery barriers—role of nanocarriers in the treatment of anterior segment ocular diseases. Pharmaceutics 10:1–31. https://doi.org/10.3390/pharmaceutics10010028
Barar J, Javadzadeh AR, Omidi Y (2008) Ocular novel drug delivery: Impacts of membranes and barriers. Expert Opin Drug Deliv 5:567–581. https://doi.org/10.1517/17425247.5.5.567
Bill A (1986) The blood-aqueous barrier. Trans Ophthalmol Soc UK 105(2):149–155
Boddu S, Gupta H, Patel S (2014) Drug delivery to the back of the eye following topical administration: an update on research and patenting activity. Recent Pat Drug Deliv Formul 8:27–36. https://doi.org/10.2174/1872211308666140130093301
Cheruvu NPS, Kompella UB (2006) Bovine and porcine transscleral solute transport. Invest Opthalmol vis Sci 47:1–7. https://doi.org/10.1167/iovs.06-0404.Bovine
Cheung ACY, Yu Y, Tay D et al (2010) Ultrasound-enhanced intrascleral delivery of protein. Int J Pharm 401:16–24. https://doi.org/10.1016/j.ijpharm.2010.09.001
Chiang B, Venugopal N, Edelhauser HF, Prausnitz MR (2016) Distribution of particles, small molecules and polymeric formulation excipients in the suprachoroidal space after microneedle injection. Exp Eye Res 153:101–109. https://doi.org/10.1016/j.exer.2016.10.011
Chirila TV, Harkin DG (2016) Biomaterials and regenerative medicine in ophthalmology, 2nd edn. Elsevier, Amsterdam
Chopra P, Hao J, Li SK (2010) Iontophoretic transport of charged macromolecules across human sclera. Int J Pharm 388:107–113. https://doi.org/10.1016/j.ijpharm.2009.12.046
Christoforidis JB, Chang S, Jiang A et al (2012) Intravitreal devices for the treatment of vitreous inflammation. Mediators Inflamm. https://doi.org/10.1155/2012/126463
Cunha-Vaz J, Bernardes R, Lobo C (2011) Blood-retinal barrier. Eur J Ophthalmol 21:3–9. https://doi.org/10.5301/EJO.2010.6049
Eljarrat-Binstock E, Pe’er J, Domb AJ, (2010) New techniques for drug delivery to the posterior eye segment. Pharm Res 27:530–543. https://doi.org/10.1007/s11095-009-0042-9
Eljarrat-Binstock E, Raiskup F, Frucht-Pery J, Domb AJ (2004) Hydrogel probe for iontophoresis drug delivery to the eye. J Biomater Sci Polym Ed 15:397–413. https://doi.org/10.1163/156856204323005271
Falavarjani KG, Nguyen QD (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye 27:787–794. https://doi.org/10.1038/eye.2013.107
Fangueiro JF, Silva AM, Garcia ML, Souto EB (2015) Current nanotechnology approaches for the treatment and management of diabetic retinopathy. Eur J Pharm Biopharm 95:307–322. https://doi.org/10.1016/j.ejpb.2014.12.023
Freddo TF (2001) Shifting the paradigm of the blood-aqueous barrier. Exp Eye Res 73:581–592. https://doi.org/10.1006/exer.2001.1056
Fujisawa T, Miyai H, Hironaka K et al (2012) Liposomal diclofenac eye drop formulations targeting the retina: Formulation stability improvement using surface modification of liposomes. Int J Pharm 436:564–567. https://doi.org/10.1016/j.ijpharm.2012.07.024
García-Estrada P, García-Bon MA, López-Naranjo EJ et al (2021) Polymeric implants for the treatment of intraocular eye diseases: trends in biodegradable and non-biodegradable materials. Pharmaceutics. https://doi.org/10.3390/pharmaceutics13050701
Gaudana R, Ananthula HK, Parenky A, Mitra AK (2010) Ocular drug delivery. AAPS J 12:348–360. https://doi.org/10.1208/s12248-010-9183-3
Ghate D, Edelhauser HF (2006) Ocular drug delivery. Expert Opin Drug Deliv 3:275–287. https://doi.org/10.1517/17425247.3.2.275
Gilger BC, Wilkie DA, Clode AB et al (2010) Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis. Vet Ophthalmol 13:294–300. https://doi.org/10.1111/j.1463-5224.2010.00807.x
Goel M, Picciani RG, Lee RK, Bhattacharya SK (2010) Aqueous humor dynamics: a review. Open Ophthalmol J 4:52–59. https://doi.org/10.2174/1874364101004010052
Good TJ, Kimura AE, Mandava N, Kahook MY (2011) Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 95:1111–1114. https://doi.org/10.1136/bjo.2010.180729
Gote V, Sikder S, Sicotte J, Pal D (2019) Ocular drug delivery: Present innovations and future challenges. J Pharmacol Exp Ther 370:602–624. https://doi.org/10.1124/jpet.119.256933
Güngör S, Delgado-Charro MB, Ruiz-Perez B et al (2010) Trans-scleral iontophoretic delivery of low molecular weight therapeutics. J Control Release 147:225–231. https://doi.org/10.1016/j.jconrel.2010.07.107
Gutiérrez-Hernández J-C, Caffey S, Abdallah W et al (2014) One-year feasibility study of replenish MicroPump for intravitreal drug delivery: a pilot study. Transl vis Sci Technol 3:1. https://doi.org/10.1167/tvst.3.4.1
Haghjou N, Soheilian M, Abdekhodaie MJ (2011) Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic vis Res 6:317–319
Hämäläinen KM, Kananen K, Auriola S et al (1997) Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Investig Ophthalmol vis Sci 38:627–634
Hartman RR, Kompella UB (2018) Intravitreal, subretinal, and suprachoroidal injections: Evolution of microneedles for drug delivery. J Ocul Pharmacol Ther 34:141–153. https://doi.org/10.1089/jop.2017.0121
He Y, Wang JC, Liu YL et al (2006) Therapeutic and toxicological evaluations of cyclosporine A microspheres as a treatment vehicle for uveitis in rabbits. J Ocul Pharmacol Ther 22:121–131. https://doi.org/10.1089/jop.2006.22.121
Hiral J, Shah JNS (2014) Nanoparticulate transscleral ocular drug delivery. J Biomol Res Ther. https://doi.org/10.4172/2167-7956.1000116
Hironaka K, Inokuchi Y, Tozuka Y et al (2009) Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J Control Release 136:247–253. https://doi.org/10.1016/j.jconrel.2009.02.020
Hoang QV, Mendonca LS, Della Torre KE et al (2012) Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 119:321–326. https://doi.org/10.1016/j.ophtha.2011.08.011
Hosoya KI, Lee VHL, Kim KJ (2005) Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur J Pharm Biopharm 60:227–240. https://doi.org/10.1016/j.ejpb.2004.12.007
Huang AJW, Tseng SCG, Kenyon KR (1989) Paracellular permeability of corneal and conjunctival epithelia. Investig Ophthalmol vis Sci 30:684–689
Huang D, Chen YS, Rupenthal ID (2018) Overcoming ocular drug delivery barriers through the use of physical forces. Adv Drug Deliv Rev 126:96–112. https://doi.org/10.1016/j.addr.2017.09.008
Huang D, Chen YS, Thakur SS, Rupenthal ID (2017) Ultrasound-mediated nanoparticle delivery across ex vivo bovine retina after intravitreal injection. Eur J Pharm Biopharm 119:125–136. https://doi.org/10.1016/j.ejpb.2017.06.009
Huang D, Wang L, Dong Y et al (2014) A novel technology using transscleral ultrasound to deliver protein loaded nanoparticles. Eur J Pharm Biopharm 88:104–115. https://doi.org/10.1016/j.ejpb.2014.04.011
Hussain AA, Starita C, Hodgetts A, Marshall J (2010) Macromolecular diffusion characteristics of ageing human Bruch’s membrane: Implications for age-related macular degeneration (AMD). Exp Eye Res 90:703–710. https://doi.org/10.1016/j.exer.2010.02.013
Huu VAN, Luo J, Zhu J et al (2015) Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye. J Control Release 200:71–77. https://doi.org/10.1016/j.jconrel.2015.01.001
Imperiale JC, Acosta GB, Sosnik A (2018) Polymer-based carriers for ophthalmic drug delivery. J Control Release 285:106–141. https://doi.org/10.1016/j.jconrel.2018.06.031
Jaffe GJ, Martin D, Callanan D et al (2006) Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis. Thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113:1020–1027. https://doi.org/10.1016/j.ophtha.2006.02.021
Jiang J, Moore JS, Edelhauser HF, Prausnitz MR (2009) Intrascleral drug delivery to the eye using hollow microneedles. Pharm Res 26:395–403. https://doi.org/10.1007/s11095-008-9756-3
Jumelle C, Gholizadeh S, Annabi N, Dana R (2020) Advances and limitations of drug delivery systems formulated as eye drops. J Control Release 321:1–22. https://doi.org/10.1016/j.jconrel.2020.01.057
Jun EJ, Won MA, Ahn J et al (2011) An antiviral small-interfering RNA simultaneously effective against the most prevalent enteroviruses causing acute hemorrhagic conjunctivitis. Investig Ophthalmol vis Sci 52:58–63. https://doi.org/10.1167/iovs.09-5051
Kane FE, Burdan J, Cutino A, Green KE (2008) IluvienTM: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 5:1039–1046. https://doi.org/10.1517/17425247.5.9.1039
Kim H, Robinson SB, Csaky KG (2009) Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm Res 26:329–337. https://doi.org/10.1007/s11095-008-9745-6
Kim HM, Ha S, Hong HK et al (2020) Intraocular distribution and kinetics of intravitreally injected antibodies and nanoparticles in rabbit eyes. Transl vis Sci Technol 9:1–11. https://doi.org/10.1167/tvst.9.6.20
Kim HM, Woo SJ (2021) Ocular drug delivery to the retina: current innovations and future perspectives with the help of tissue engineering , hydrogels, micro- and nanoparticles, and sever intravitreally administered drug delivery systems have been investigated. These s conj
Kompella UB, Amrite AC, Pacha Ravi R, Durazo SA (2013) Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res 36:172–198. https://doi.org/10.1016/j.preteyeres.2013.04.001
Kristensen M, Birch D, Nielsen HM (2016) Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos. Int J Mol Sci. https://doi.org/10.3390/ijms17020185
Kuno BN, Fujii S (2012) Ocular drug delivery systems for the posterior segment: a review. Retin Today 58:54–59
Labelle P (2017) The eye. In: Zachary JFBT-PB of VD, 6th edn. Pathologic basis of veterinary disease. Elsevier, pp 1265–1318.e1
Lanzetta P, Loewenstein A (2017) Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases. Graefe’s Arch Clin Exp Ophthalmol 255:1259–1273. https://doi.org/10.1007/s00417-017-3647-4
Lee B, Litt M, Buchsbaum G (1992) Rheology of the vitreous body. Part I: viscoelasticity of human vitreous. Biorheology 29:521–533. https://doi.org/10.3233/bir-1992-295-612
Lee B, Litt M, Buchsbaum G (1994a) Rheology of the vitreous body. Part 2: viscoelasticity of bovine and porcine vitreous. Biorheology 31:327–338. https://doi.org/10.3233/bir-1994-31403
Lee B, Litt M, Buchsbaum G (1994b) Rheology of the vitreous body. Part 3: concentration of electrolytes, collagen and hyaluronic acid. Biorheology 31:339–351. https://doi.org/10.3233/bir-1994-31404
Lee SJ, He W, Robinson SB et al (2010) Evaluation of clearance mechanisms with transscleral drug delivery. Investig Ophthalmol vis Sci 51:5205–5212. https://doi.org/10.1167/iovs.10-5337
Liu H, Zeng F, Zhang M et al (2016) Emerging landscape of cell penetrating peptide in reprogramming and gene editing. J Control Release 226:124–137. https://doi.org/10.1016/j.jconrel.2016.02.002
Malh M, Aj Umdar KM (2001) Permeation through cornea. Indian J Exp Biol 39:11–24
Mann BK, Stirland DL, Lee HK, Wirostko BM (2018) Ocular translational science: A review of development steps and paths. Adv Drug Deliv Rev 126:195–203. https://doi.org/10.1016/j.addr.2018.01.012
Millar TJ, Schuett BS (2015) The real reason for having a meibomian lipid layer covering the outer surface of the tear film: a review. Exp Eye Res 137:125–138. https://doi.org/10.1016/j.exer.2015.05.002
Mitra AK, Anand BS, Duvvuri S (2005) Drug Delivery to the Eye. In: Ashim K. Mitra, Banmeet S. Anand SD (ed) Advances in Organ Biology. pp 307–351. https://doi.org/10.1016/S1569-2590(05)10012-3
Mitra M, Kandalam M, Rangasamy J et al (2013) Novel epithelial cell adhesion molecule antibody conjugated polyethyleneimine-capped gold nanoparticles for enhanced and targeted small interfering RNA delivery to retinoblastoma cells. Mol vis 19:1029–1038
Molokhia SA, Sant H, Simonis J et al (2010) The capsule drug device: novel approach for drug delivery to the eye. Vision Res 50:680–685. https://doi.org/10.1016/j.visres.2009.10.013
Nabili M, Patel H, Mahesh SP et al (2013) Ultrasound-enhanced delivery of antibiotics and anti-inflammatory drugs into the eye. Ultrasound Med Biol 39:638–646. https://doi.org/10.1016/j.ultrasmedbio.2012.11.010
Nayak K, Misra M (2018) A review on recent drug delivery systems for posterior segment of eye. Biomed Pharmacother 107:1564–1582. https://doi.org/10.1016/j.biopha.2018.08.138
Olsen TW, Edelhauser HF, Lim JI, Geroski DH (1995) Human scleral permeability: Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Investig Ophthalmol vis Sci 36:1893–1903
Papangkorn K, Prendergast E, Higuchi JW et al (2017) Noninvasive ocular drug delivery system of dexamethasone sodium phosphate in the treatment of experimental uveitis rabbit. J Ocul Pharmacol Ther 33:753–762. https://doi.org/10.1089/jop.2017.0053
Papangkorn K, W. Higuchi J, Brar B, I. Higuchi W, (2019) A novel ocular drug delivery system of dexamethasone sodium phosphate for noninfectious uveitis treatment. Adv Diagnosis Manag Uveitis. https://doi.org/10.5772/intechopen.82388
Patel SR, Berezovsky DE, McCarey BE et al (2012) Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Investig Ophthalmol vis Sci 53:4433–4441. https://doi.org/10.1167/iovs.12-9872
Pe’er J, Damato ADSBE (eds) (2014) Clinical ophthalmic oncology. Springer International Publishing, New York
Perez VL, Wirostko B, Korenfeld M et al (2020) Ophthalmic drug delivery using iontophoresis: Recent clinical applications. J Ocul Pharmacol Ther 36:75–87. https://doi.org/10.1089/jop.2019.0034
Pescina S, Martini D, Santi P et al (2013) In vitro trans-scleral iontophoresis of methylprednisolone hemisuccinate with short application time and high drug concentration. Int J Pharm 451:12–17. https://doi.org/10.1016/j.ijpharm.2013.04.066
Peynshaert K, Devoldere J, De Smedt SC, Remaut K (2018) In vitro and ex vivo models to study drug delivery barriers in the posterior segment of the eye. Adv Drug Deliv Rev 126:44–57. https://doi.org/10.1016/j.addr.2017.09.007
Pitkänen L, Ruponen M, Nieminen J, Urtti A (2003) Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharm Res 20:576–583. https://doi.org/10.1023/a:1023238530504
Prausnitz MR (1998) Permeability of cornea, sciera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci 87:1479–1488. https://doi.org/10.1021/js9802594
Quinones K, Foster CS (2008) Management of the patient with ocular allergy. In: Krouse JH, Derebery MJ, Chadwick SJ (eds) Managing the allergic patient. W.B Saunders, Edinburgh, pp 145–174
Rivers HM, Ray Chaudhuri S, Shah JC, Mittal S (2015) A new vision for the eye: unmet ocular drug delivery needs. Pharm Res 32:2814–2823. https://doi.org/10.1007/s11095-015-1717-z
Rowe-Rendleman CL, Durazo SA, Kompella UB et al (2014) Drug and gene delivery to the back of the eye: From bench to bedside. Investig Ophthalmol vis Sci 55:2714–2730. https://doi.org/10.1167/iovs.13-13707
Scaramuzzi M, Querques G, La SC et al (2015) Repeated intravitreal dexamethasone implant (ozurdex) for diabetic macular EDEMA. Retina 35:1216–1222. https://doi.org/10.1097/IAE.0000000000000443
Schopf LR, Popov AM, Enlow EM et al (2015) Topical ocular drug delivery to the back of the eye by mucus-penetrating particles. Transl vis Sci Technol. https://doi.org/10.1167/tvst.4.3.11
Sharma M, Deohra A, Reddy KR, Sadhu V (2019) Chapter 5:biocompatible in-situ gelling polymer hydrogels for treating ocular infection. In: Gurtler V, Ball AS, Soni SBTM (eds) Nanotechnology. Academic Press, Cambridge, pp 93–114
Sharma R, Yassin AE (2014) Nanostructure-based platforms-current prospective in ophthalmic drug delivery. Indian J Ophthalmol 62:768–772. https://doi.org/10.4103/0301-4738.138301
Sonoda S, Tachibana K, Uchino E et al (2006) Gene transfer to corneal epithelium and keratocytes mediated by ultrasound with microbubbles. Investig Ophthalmol vis Sci 47:558–564. https://doi.org/10.1167/iovs.05-0889
Sonoda S, Tachibana K, Yamashita T et al (2012) Selective gene transfer to the retina using intravitreal ultrasound irradiation. J Ophthalmol. https://doi.org/10.1155/2012/412752
Souied EH, Reid SNM, Piri NI et al (2008) Non-invasive gene transfer by iontophoresis for therapy of an inherited retinal degeneration. Exp Eye Res 87:168–175. https://doi.org/10.1016/j.exer.2008.04.009
Stein CA, Castanotto D (2017) FDA-approved oligonucleotide therapies in 2017. Mol Ther 25:1069–1075. https://doi.org/10.1016/j.ymthe.2017.03.023
Sunkara G, Kompella UB (2003) Membrane transport processes in the eye. Ophthalmic Drug Deliv Syst Second Ed Revis Expand. https://doi.org/10.1201/9780203912072.ch2
Suri R, Beg S, Kohli K (2020) Target strategies for drug delivery bypassing ocular barriers. Elsevier B.V., Amsterdam
Thakur Singh RR, Tekko I, McAvoy K et al (2017) Minimally invasive microneedles for ocular drug delivery. Expert Opin Drug Deliv 14:525–537. https://doi.org/10.1080/17425247.2016.1218460
Than A, Liu C, Chang H et al (2018) Self-implantable double-layered micro-drug-reservoirs for efficient and controlled ocular drug delivery. Nat Commun 9:1–12. https://doi.org/10.1038/s41467-018-06981-w
Urtti A (2006) Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 58:1131–1135. https://doi.org/10.1016/j.addr.2006.07.027
Varela-Fernández R, Díaz-Tomé V, Luaces-Rodríguez A et al (2020) Drug delivery to the posterior segment of the eye: Biopharmaceutic and pharmacokinetic considerations. Pharmaceutics 12:1–39. https://doi.org/10.3390/pharmaceutics12030269
Waghule T, Singhvi G, Dubey SK et al (2019) Microneedles: a smart approach and increasing potential for transdermal drug delivery system. Biomed Pharmacother 109:1249–1258. https://doi.org/10.1016/j.biopha.2018.10.078
Wang Y, Rajala A, Rajala R (2015) Lipid nanoparticles for ocular gene delivery. J Funct Biomater 6:379–394. https://doi.org/10.3390/jfb6020379
Watsky MA, Jablonski MM, Edelhauser HF (1988) Comparison of conjunctival and corneal surface areas in rabbit and human. Curr Eye Res 7:483–486. https://doi.org/10.3109/02713688809031801
Watson PG, Young RD (2004) Scleral structure, organisation and disease: a review. Exp Eye Res 78:609–623. https://doi.org/10.1016/S0014-4835(03)00212-4
Weng Y, Liu J, Jin S et al (2017) Nanotechnology-based strategies for treatment of ocular disease. Acta Pharm Sin B 7:281–291. https://doi.org/10.1016/j.apsb.2016.09.001
Worakul N, Robinson JR (1997) Ocular pharmacokinetics/pharmacodynamics. Eur J Pharm Biopharm 44:71–83. https://doi.org/10.1016/S0939-6411(97)00064-7
Yellepeddi VK, Palakurthi S (2016) Recent advances in topical ocular drug delivery. J Ocul Pharmacol Ther 32:67–82. https://doi.org/10.1089/jop.2015.0047
Ying L, Tahara K, Takeuchi H (2013) Drug delivery to the ocular posterior segment using lipid emulsion via eye drop administration: effect of emulsion formulations and surface modification. Int J Pharm 453:329–335. https://doi.org/10.1016/j.ijpharm.2013.06.024
Zderic V, Vaezy S, Martin RW, Clark JI (2002) Ocular drug delivery using 20-kHz ultrasound. Ultrasound Med Biol 28:823–829. https://doi.org/10.1016/S0301-5629(02)00515-X
Acknowledgements
This research was supported by a Grant (NRF-2018R1D1A1B07049971) from the Basic Science Research Program through the National Research Foundation (NRF) funded by the Ministry of Education, Science, and Technology, Republic of Korea.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors (J. Lee, and Y.S. Rhee) declare that they have no conflicts of interest.
Research involving human and/or animal participants
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lee, J., Rhee, YS. Ophthalmic dosage forms for drug delivery to posterior segment. J. Pharm. Investig. 52, 161–173 (2022). https://doi.org/10.1007/s40005-021-00554-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40005-021-00554-8